ArticleAsia-Pacific journal of oncology nursing2025
COVID-19 related symptoms and the second infection status of SARS-CoV-2 in patients with lung cancer: A single-center, six-month longitudinal observational study.
Article in Asia-Pacific journal of oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to delineate the occurrence and duration of the symptoms of coronavirus disease 2019 (COVID-19) in patients with lung cancer to provide supporting data for clinical research and epidemic prevention and control. Methods: This prospective longitudinal study was conducted in a tertiary hospital in China, comprising 697 outpatients and inpatients with lung cancer seeking medical care between March and April 2023. The enrolled patients completed questionnaires during the visit, with subsequent follow-up by telephone at 6 months after the patients' first infection. The questionnaire covered general patient information, disease characteristics, and SARS-CoV-2 infection and vaccine status. The details of COVID-19 treatment included the diagnostic method, infection time, and lung cancer treatment for up to three months after infection. This study also investigated the symptoms and duration of COVID-19. Results: Among 697 patients, 591 (84.79%) had a history of COVID-19, 165 patients (27.92%) were not vaccinated, and 339 (57.36%) received the recommended ≥ 3 doses of the COVID-19 vaccine, yielding a 72.08% overall vaccination rate. The predominant symptoms of the initial SARS-CoV-2 infection included fever (79.53%), muscle pain (49.24%), cough (48.22%), sore throat (46.02%), and fatigue (35.36%). Patients who were infected with COVID-19 after the lung cancer diagnosis and received systematic treatment exhibited significant differences in muscle pain (χ Conclusions: Our analysis suggests that COVID-19 has a high infection rate in patients with lung cancer, but the duration of different symptoms varies. Patients with a first SARS-CoV-2 diagnosis who had previously been treated for oncology experienced less severe pain-related symptoms than patients with lung cancer diagnosed after infection. COVID-19 vaccines have demonstrated protective effects by mitigating symptom severity following a second infection. Suggest that we should further explore ways to reduce the morbidity, severity, and mortality of COVID-19 while ensuring adherence to patients' standard treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.